Gilead Sciences, Inc.

Gilead Sciences, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Gilead Sciences, Inc. is a biopharmaceutical company that researches and develops treatments and drugs. Its work has helped to treat HIV/AIDS, heart and liver diseases, cancers, respiratory diseases including COVID-19, and more.

Ticker: GILD

Humankind Value: $205.9 B

Revenue: $25.9 B

Market Cap: $74.5 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Gilead operates in a manner that is net positive for humanity, largely because of its contributions to Healthcare R&D ($117.9 B), Pharmaceuticals ($80.2 B), and Economic Value ($7.4 B). Healthcare is central to our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. The company produces economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. This company’s downsides are its association with Greenhouse Gases (-$2.0 B) and Air Pollution (-$410.2 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings